INAB: IN8bio, Inc Price-to-Revenue Coefficient

Corporate company logo of IN8bio Inc (INAB)

IN8bio, Inc. is implementing energy-efficient bioreactors and maintaining strict control over biomaterial disposal. The price-to-sales multiple helps identify market confidence in revenue, with the current value standing at . Experienced cell therapy leaders ensure transparency of R&D budgets and proficient interaction with regulators. The strategy is focused on completing mid-stage trials of gamma-delta T-cells and developing proprietary laboratory logistics to combat blood cancers.

INAB (IN8bio, Inc.) Market Capitalization-to-Revenue Ratio history from 07/04/2022 to 11/13/2026

Comprehensive metric breakdowns and analytics for IN8bio, Inc (INAB)

- stock price and consensus target price:
Share Price in8bio.com|INAB - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization IN8bio, Inc|INAB - Total Company Value
- company book value details:
Equity per Share IN8bio|INAB - Accounting Value of Company|Market Capitalization to Book Value Ratio in8bio.com|INAB - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital IN8bio, Inc.|INAB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity IN8bio Inc|INAB - Company Cumulative Debt|Debt to Book Value IN8bio, Inc|INAB - Company Long-Term Loans and Borrowings|Company Short-Term Debts IN8bio|Quick Liquidity in8bio.com
- net income and valuation multiples indicators:
INAB - Company Profit|Projected Future Earnings IN8bio, Inc.|INAB - Price to Earnings Ratio|Projected Price to Earnings IN8bio Inc.|INAB - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple IN8bio, Inc|INAB - Operating income before deduction of amortization|Earnings per share for the last twelve months IN8bio|INAB - Earnings per share for the last 12 months|Quarterly EPS earnings growth in8bio.com|INAB - Earnings growth in current year|Earnings growth forecast for next year IN8bio, Inc.
- revenue and sales proceeds data:
INAB - Company Revenue|Projected Sales Volume in8bio.com|INAB - Market Cap to Revenue|Forward P/S Multiple IN8bio, Inc
Fundamental company valuation:INAB (in8bio.com)
Signature product of IN8bio Inc

The P/S chart allows for a comparison of the market capitalization of IN8bio, Inc. (INAB) against its current sales volume, reflecting the degree of asset overvaluation within the context of cell therapy development. This ratio is calculated by dividing the company's value by its revenue, helping investors assess the value of intellectual property and the monetization potential of patents for treating oncohematological diseases.

Main competitors

tgtherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple ACLX (Arcellx, Inc.)|Price-to-Revenue Coefficient Disc Medicine Inc (IRON)|SNDX - Price-to-Revenue Ratio|KURA (Kura) - Market Cap to Revenue Ratio|Market Capitalization-to-Revenue Ratio ADC Therapeutics ADCT|Foghorn Therapeutics Inc. (FHTX) - P/S Multiple|Price-to-Revenue Ratio Vor Biopharma|P/S Multiple Nkarta Corp|COEP (Coeptis Therapeutics) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio ATNM (Actinium Corp)|ESLA: Price to Sales|CASI - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio Marker Bio (MRKR)|ERNA - P/S Multiple|GT Biopharma Corp - Price-to-Revenue Coefficient|APTO (Aptose Biosciences) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio Bio-Path Holdings (BPTH)|P/S Multiple meipharma.com|Market Cap to Revenue VINC (Vincerx Pharma, Inc.)